Mobius Theraputics™ Receives Key Mitosol® Approval For 2014
ST. LOUIS, MO--(Marketwired - January 13, 2014) -
Highlighted Links |
https://www.mobiustherapeutics.com/ |
"As the convenience, containment, and consistency aspects of Mitosol® remain unprecedented, this economic assurance allows providers to know their concerns regarding ophthalmic mitomycin are answered by a single, FDA approved product," said Ed Timm, President and CEO of Mobius Therapeutics. "We know all payors look to Medicare's expertise, and we expect to continue to see broad coverage of Mitosol®. We applaud CMS in assuring existing and new Mitosol® patients and providers economic security. Access to Mitosol® will meet their needs, both clinical and financial, regardless of the site of service," said Timm.
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Please see full prescribing information at www.MobiusTherapeutics.com Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.
CONTACT:
Jim Anderson
Mobius Therapeutics, LLC
314-615-6930
Email Contact
Andy Likes
The Vandiver Group, Inc.
314-606-1878
Email Contact
Help employers find you! Check out all the jobs and post your resume.